The Application Submission for the Academic Grant Program is now closed.
Congratulations to the winners! Check back for updates on future grant cycles.
The Application Submission for the Academic Grant Program is now closed.
Congratulations to the winners! Check back for updates on future grant cycles.
Request a Model to be added to the 'Academic Grant Program'.
Taconic invites scientists in the nonprofit sector to apply for a grant to support their research. Grants are awarded in the form of Taconic animals to support a specified research project. The list of animal models available for grants will update with each cycle. The number of grants awarded will depend on the quality of the applications and the cumulative number of animals requested. Ten grants were awarded following the 2021 Q3 cycle. Those applicants who do not receive a grant will receive a discount towards a future purchase.
For awardees seeking larger grants from funding agencies, Taconic can provide a letter of support describing the grant award and our support for the research project.
The grant program is open to academic, government and non-profit researchers in North America and Europe. Proposals will be accepted from principal investigators, project scientists, postdoctoral fellows, graduate students, and staff scientists. Applications from junior scientists should include a letter of support for the project from that scientist's principal investigator or group leader.
Applications will be evaluated by a panel of Taconic scientists and scored based on scientific merit, technical feasibility, choice of appropriate animal model(s), applicant's biosketch (CV), and relation to priority research area.
The success of a project rests in part on selection of an appropriate animal model for the scientific question. Taconic's Field Application Scientists are available to consult with you. To schedule a complimentary scientific consultation, fill out this form.
The deadline to submit an application for this cycle was 5 PM ET May 27, 2022. Grantees will be notified within two months after the deadline.
Successful applicants will need to receive grant animals within 6 months after notification of award. Timeline extensions may be granted if there are supply-side delays. Timeline extensions may be granted for other special considerations; for instance, if the study design involves staggering animals into study cohorts that require trialing in non-overlapping stages. Unclaimed award animals may be forfeited.
Taconic strongly recommends that applicants pursue approval from their institution's relevant agencies to ensure deadlines can be realistically met. This may include proactive engagement of the IACUC for protocol approvals; human resources for personnel recruitment; procurement for sourcing of equipment, materials; and third-party service providers for contracted assays.
Information contained in grant applications will be held confidential by Taconic. Scientists who accept a grant agree that Taconic may use the grantee's likeness, name, and a mutually agreed upon project title for publicity purposes. Grant winners will be asked to submit a headshot photo or a photo of their lab and links to their institutional profile web page, lab web page, and/or social media platforms for Taconic's announcement of the cycle's winners.
While Taconic will accept applications for any project involving the models being offered in this cycle, the models have been assigned into disease area portfolios and preference will be given to projects that are best aligned with priority research areas. Each application may request one or more models within a portfolio, and the applicant should consult the caps presented in the model tables with regards to quantity limits. Final numbers should be scientifically justified within the project proposal. The awards will be bestowed in the form of animals, not in the form of financial sponsorship or compensation. Applicants may submit multiple project proposals (maximum 2 applications per applicant) in the same or different portfolios, but each of these proposals should stand alone as a unique, complete submission package rather than being bundled into a single application. Each application will be judged independently.
Special considerations:
Model | Model # | Available sex | Available health standard | Award max (# of animals) | Priority research areas |
Abb KO HLA-DR4 random transgenic | 4149 | F, M | MPF | 50 F + 50 M | Arthritis; type 1 diabetes; novel models of autoimmunity |
TNF-α random transgenic | 1006 | F, M | MPF | 50 F + 50 M* longer lead time expected | Role of immune cells in rheumatoid arthritis; novel adjunct therapies for refractory rheumatoid arthritis |
C57BL/6 NTac | B6 | F, M | MPF | N/A | Wild type control for 4149 |
* Consultation recommended regarding lead times
Model | Model # | Available sex | Available health standard | Award max (# of animals) | Priority research areas |
Jh | 17758 (B6) or 1147 (BALB/c) | F | MPF | 100 F | Syngeneic tumor modeling; B cell characterization; B cell therapies; B cell driven diseases |
FcγRII constitutive knockout | 580 | F, M | MPF | 30 F + 30 M* | Syngeneic tumor modeling |
C57BL/6 | B6 | F, M | MPF | N/A | Wild type control for 17758, 580 |
BALB/c | BALB | F | MPF | N/A | Wild type control for 1147 |
* Consultation recommended regarding lead times and age ranges acceptable
Model | Model # | Available sex | Available health standard | Award max (# of animals) | Priority research areas |
ARTE10 (APP-PS1) random transgenic | 16347 | F, M | MPF | 50 F, 50 M | Insights into processes driving disease, including inflammation, senescence, fibrosis, endocytic trafficking, protein handling, and aggregation; microglial and astrocyte targeting therapeutics |
APPSWE B6;SJL random transgenic | 1349 | F, M | MPF | 50 F, 50 M | Insights into processes driving disease, including inflammation, senescence, fibrosis, endocytic trafficking, protein handling, and aggregation; microglial and astrocyte targeting therapeutics; head-to-head comparison of model to #2789 |
APPSWE 129S6 random transgenic | 2789 | F, M | MPF | 50 F*, 50 M* | Insights into processes driving disease, including inflammation, senescence, fibrosis, endocytic trafficking, protein handling, and aggregation; microglial and astrocyte targeting therapeutics; head-to-head comparison of model to #1349 |
Tau random transgenic | 2508 | F, M | MPF | 50 F, 50 M | Insights into processes driving disease, including inflammation, senescence, fibrosis, endocytic trafficking, protein handling, and aggregation; microglial and astrocyte targeting therapeutics |
Df(h22q11) deletion | 11026 | F, M | MPF | 30 F*, 30 M* | Basic characterization and translational drug development |
C57BL/6 | B6 | F, M | MPF | N/A | Wild type control for 16347 and 11026 |
C57BL/6, DBA/2, SW mixed background | 18392 | F, M | MPF | N/A | Wild type control for 2508 |
*Consultation recommended regarding lead times
Model | Model # | Available sex | Available health standard | Award max (# of animals) | Priority research areas |
Diet Induced NASH B6 | NASH-B6 | M | MPF | 120 M | Effects of underlying metabolic disease on cancer; chemokine and cytokine profiling; senescence; apoptosis; oxidative stress; translational biomarker characterization; novel druggable targets; adoptive transfer of disease |
Diet induced obese B6 (DIO) | DIO-B6 | M | MPF | 120 M | Effects of underlying metabolic disease on cancer |
NASH control (age matched) | NASH-B6-CONTROL | M | MPF | 30 M | Diet control for NASH-B6 |
DIO control (age matched) | DIO-B6-CONTROL | M | MPF | 30 M | Diet control for DIO-B6 |